Drugs / MK-6598
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05594043 | Dec 2022 → May 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-6598 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05594043 ↗ |
| Route | Oral | “Oral tablet” NCT05594043 ↗ |